Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer

NCT ID: NCT01229865

Last Updated: 2018-10-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 29 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-12-31
• Study Completion Date: 2016-06-30

Brief Summary

The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC.

Conditions

Differential Thyroid Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

VB-111

antiangiogenic and vascular disruptive agent

Group Type: EXPERIMENTAL

VB-111

Intervention Type: DRUG

Interventions

VB-111

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Histologically or cytologically confirmed advanced DTC (papillary, follicular, Hurthle cell);

2. Absence of sensitivity to therapeutic radioiodine;

3. Measurable disease, defined as at least one non-bony lesion that can be accurately measured in at least one dimension as confirmed with spiral CT scan

4. Life expectancy >3 months; ECOG performance status (PS) 0, 1, or 2; Karnofsky performance status of ≥60%;

5. Subjects with a normal/acceptable hematological profile

6. Subjects with adequate renal function

Exclusion Criteria

1. Presence of any of the following:

• Radiotherapy or chemotherapy <4 weeks prior to baseline visit; (Concurrent and/or prior therapy with octreotide will be allowed, provided tumor progression on this therapy has been demonstrated; Concurrent and/or prior therapy with biphosphonates will be allowed)
• Radiotherapy to ≥25% of bone marrow;

2. Major surgery <4 weeks prior to baseline visit;

3. Any other ongoing investigational agents within 4 weeks before dosing;

4. Subjects who suffered from an acute cardiac event within the last 12 months, including myocardial infarction, cardiac arrythmia, admission for unstable angina, cardiac angioplasty, or stenting;

5. QTc prolongation (defined as QTc interval ≥500 msecs) or other significant ECG abnormalities (e.g. frequent ventricular ectopy, evidence of ongoing myocardial ischemia);

6. Subjects with active vascular disease, either myocardial or peripheral;

7. Subjects with proliferative and/or vascular retinopathy;

8. Subjects with known active liver disease (alcoholic, drug/toxin induced, genetic, or autoimmune) other than related to tumor metastases;

9. Subjects with known CNS metastatic disease (Exception: Subjects with treated CNS metastases stable by radiographic examinations >6 months after definitive therapy administered, are eligible);

10. Subjects testing positive to one of the following viruses: HIV, HBV or HCV;

11. Any of the following conditions:

• Serious or non-healing wound, ulcer, or bone fracture;
• History of abdominal fistula, gastro-intestinal perforation, active diverticulitis, intra-abdominal abscess or gastro-intestinal tract bleeding within 6 months of dosing;
• Any history of cerebrovascular accident (CVA) within 6 months of dosing;
• Current use of therapeutic warfarin (Note: Low molecular weight heparin and prophylactic low-dose warfarin [INR<1.2 X ULN] are permitted);
• History of bleeding disorder, including subjects with hemophilia, disseminated intravascular coagulation (DIC), or any other abnormality of coagulation potentially predisposing subjects to bleeding;
• Poorly controlled depression or anxiety disorder, or recent (within the previous 6 months) suicidal ideation;

12. Subjects with an ongoing requirement for immunosuppressive treatment, including the use of glucocorticoids or cyclosporin, or with a history of chronic use of any such medication within the last 4 weeks before dosing;

13. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Vascular Biogenics Ltd. operating as VBL Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Mayo Clinic

Jacksonville, Florida, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

Countries

United States

Other Identifiers

VB-111-103

Identifier Type: -

Identifier Source: org_study_id